The trial is jointly conducted at the Fudan University Shanghai Cancer Center and Peking University Cancer Hospital.

EVM16 is a novel personalized therapeutic mRNA cancer vaccine internally developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...

The immunotherapeutic efficacy of M@P is further demonstrated in a tumor-bearing mouse model with poor immunogenicity. M@P can promote the production of tumor-specific antigens and the maturation ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...